{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:14:45Z","timestamp":1790075685191,"version":"4.0.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Neuroepithelial tumors (NEpT) harboring <jats:italic>EWSR::PATZ1<\/jats:italic> fusions remain an enigma. Initially described in sarcomas, these tumors display remarkable histomorphological diversity and unpredictable clinical behavior based on histologic or molecular features, with no established management protocols. To date, this subgroup of neoplasms has not been acknowledged as a <jats:italic>sui generis<\/jats:italic> entity by the WHO classification system, and it is currently designated as \u2018NEC\u2019\/\u2019NOS\u2019. This retrospective case series describes two young adults (32\u201335 years old) without cancer predisposition or risk factors, diagnosed with <jats:italic>EWSR1::PATZ1<\/jats:italic>-fused NEpT. Case 1, a female with seizures, presented a heterogeneous left parietal lobe lesion (4.0 \u00d7 3.2 \u00d7 3.6 cm), classified as high-grade NEpT with <jats:italic>MGMT<\/jats:italic> promoter methylation, a calibrated score of 0.95 (\u2265 0.9), and a co-occurring somatic <jats:italic>MUTYH<\/jats:italic> mutation. Case 2, a male with chronic headaches and mild right-sided paresthesia, had a left frontotemporal lesion (3.0 \u00d7 2.8 \u00d7 3.4 cm), initially diagnosed as an extraventricular neurocytoma but later reclassified as a NEpT with low-to-intermediate grade features, without MGMT methylation, and a calibrated score of 0.92. Case 1 received upfront resection, followed by Stupp protocol chemoradiation and temozolomide maintenance, resulting in 14 months of progression-free survival (PFS). Case 2 underwent subtotal resection and adjuvant radiotherapy after an 8-month recurrence, achieving 11 months of PFS to date. Both patients are asymptomatic, off corticosteroids, with the latest imaging revealing no disease progression. Our cases emphasize that <jats:italic>EWSR1::PATZ1<\/jats:italic>-fused NEpT displays a unique signature (ventricular localization, glioneuronal differentiation, and a distinct methylation cluster), supporting their inclusion in the WHO classification. Moreover, we present the first documented somatic co-mutation involving <jats:italic>MUTYH<\/jats:italic>. At present, despite the theoretical risk of temozolomide resistance due to <jats:italic>PATZ1<\/jats:italic> overexpression, our results suggest that conventional glioma therapies remain the preferred approach.<\/jats:p>","DOI":"10.3389\/fonc.2025.1604479","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:21:27Z","timestamp":1749705687000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Neuroepithelial tumors of the central nervous system with EWSR1::PATZ1 fusion: a case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Jo\u00e3o Felipe Lima","family":"Feldmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Henrique Lima","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Sales","family":"Canedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Cicci Farinha","family":"Restini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romulo Loss","family":"Mattedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Guilherme Cernaglia A.","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olavo","family":"Feher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae047","article-title":"CBTRUS statistical report: American brain tumor association & NCI neuro-oncology branch adolescent and young adult primary brain and other central nervous system tumors diagnosed in the United States in 2016\u20132020","volume":"26","author":"Price","year":"2024","journal-title":"Neuro-oncology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"100400","DOI":"10.1016\/j.modpat.2023.100400","article-title":"Sarcomas harboring EWSR1::PATZ1 fusions: A clinicopathologic study of 17 cases","volume":"37","author":"Dehner","year":"2023","journal-title":"Modern Pathol"},{"key":"B4","first-page":"865","article-title":"siRNA down-regulation of the PATZ1 gene in human glioma cells increases their sensitivity to apoptotic stimuli","volume":"6","author":"Tritz","year":"2024","journal-title":"Cancer Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nlad076","article-title":"Neuroepithelial tumor with EWSR1::PATZ1 fusion: A literature review","volume":"82","author":"Kim","year":"2023","journal-title":"J Neuropathology Exp Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.5334\/jbsr.3431","article-title":"The imaging appearance of EWSR1::PATZ1 gene fusion central nervous system tumors","volume":"108","author":"Vanmarcke","year":"2024","journal-title":"J Belgian Soc Radiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1094274","article-title":"Case report: A unique presentation of a high-grade neuroepithelial tumor with EWSR1::PATZ1 fusion with diagnostic, molecular, and therapeutic insights","volume":"13","author":"Ene","year":"2023","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12626","article-title":"A polyphenotypic Malignant paediatric brain tumour presenting a MN1-PATZ1 fusion, no epigenetic similarities with CNS High-Grade Neuroepithelial Tumour with MN1 Alteration (CNS HGNET-MN1) and related to PATZ1-fused sarcomas","volume":"46","author":"Burel-Vandenbos","year":"2020","journal-title":"Neuropathology Appl Neurobiology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-022-02405-8","article-title":"The oncogenic fusion landscape in pediatric CNS neoplasms","volume":"143","author":"Roosen","year":"2022","journal-title":"Acta Neuropathologica"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-019-02039-3","article-title":"Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions","volume":"138","author":"Stichel","year":"2019","journal-title":"Acta Neuropathologica"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1539-z","article-title":"Genetic alterations in uncommon low grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology","volume":"131","author":"Qaddoumi","year":"2016","journal-title":"Acta Neuropathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0301-1","article-title":"Clinical, pathological, and genomic features of EWSR1-PATZ1 fusion sarcoma","volume":"32","author":"Bridge","year":"2019","journal-title":"Modern Pathology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"bcr","DOI":"10.1136\/bcr-2018-226455","article-title":"Atypical central neurocytoma with novel EWSR1-ATF1 fusion and MUTYH mutation detected by next-generation sequencing","volume":"12","author":"Aghajan","year":"2019","journal-title":"BMJ Case Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2021.105136","article-title":"Antioxidant responses related to temozolomide resistance in glioblastoma","volume":"149","author":"Campos-Sandoval","year":"2021","journal-title":"Neurochemistry Int"},{"key":"B15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12929-021-00717-7","article-title":"Dissecting the mechanism of temozolomide resistance and its association with the regulatory roles of intracellular reactive oxygen species in glioblastoma","volume":"28","author":"Chien","year":"2021","journal-title":"J Biomed Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/bpa.2019.29.issue-1","article-title":"EWSR1-PATZ1 gene fusion may define a new glioneuronal tumor entity","volume":"29","author":"Siegfried","year":"2019","journal-title":"Brain Pathol (Zurich Switzerland)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"New Engl J Medicine"},{"key":"B18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13148-022-01365-w","article-title":"Sarcoma classification by DNA methylation profiling in clinical everyday life: the Charit\u00e9 experience","volume":"14","author":"Roohani","year":"2022","journal-title":"Clin Epigenet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2023.38.e356","article-title":"Brain tumor classification by methylation profile","volume":"38","author":"Park","year":"2023","journal-title":"J Korean Med Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab134","article-title":"Spatial concordance of DNA methylation classification in diffuse glioma","volume":"23","author":"Verburg","year":"2021","journal-title":"Neuro Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.3390\/ijms23105801","article-title":"Histone modifications and non-coding RNAs: mutual epigenetic regulation and role in pathogenesis","volume":"23","author":"Bure","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"New Engl J Medicine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.06.784","article-title":"A Randomized Trial of Chemotherapy Plus Radiotherapy (RT) versus RT alone for Anaplastic Oligodendroglioma (RTOG 9402): The Perspective of Longer Follow-up","volume":"72","author":"Cairncross","year":"2008","journal-title":"Int J Radiat OncologyBiologyPhysics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.2229","article-title":"Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951","volume":"31","author":"van den Bent","year":"2013","journal-title":"J Clin Oncology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-021-02354-8","article-title":"PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum","volume":"142","author":"Alhalabi","year":"2021","journal-title":"Acta Neuropathologica"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4953107","article-title":"PATZ1 induces apoptosis through PUMA in glioblastoma","volume":"2022","author":"Tao","year":"2022","journal-title":"J Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10973","article-title":"Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide","volume":"7","author":"Weyhenmeyer","year":"2016","journal-title":"Oncotarget"},{"key":"B28","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3390\/biom11040572","article-title":"Overcoming TRAIL resistance for glioblastoma treatment","volume":"11","author":"Deng","year":"2021","journal-title":"Biomolecules"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1604479\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:21:27Z","timestamp":1749705687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1604479\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":28,"alternative-id":["10.3389\/fonc.2025.1604479"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1604479","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"article-number":"1604479"}}